Tag: DTM SCS

Medtronic announces trial data on closed-loop and DTM SCS therapies at...

At this year’s North American Neuromodulation Society (NANS) annual meeting (18–21 January, Las Vegas, USA), Medtronic announced new data from two clinical trials demonstrating...

Medtronic announces results showing meaningful pain relief using DTM SCS endurance...

Medtronic has announced three-month results from an on-label, prospective, multicentre study showing meaningful pain relief using DTM SCS endurance therapy—a modified, lower-energy variation of the...

Medtronic announces schedule for sponsored presentations at NANS 2022

Medtronic has announced its schedule for presentations at the 25th North American Neuromodulation Society (NANS) annual meeting (13–15 January 2022; Orlando, USA). According to a press...
dtm scs therapy

DTM SCS: A unique, tailored and highly effective therapy option for...

Michael Fishman (Wilmington, USA) discusses the benefits of Differential Target Multiplexed spinal cord stimulation (DTM SCS; Medtronic)—when compared to more conventional SCS therapy options—and...
medtronic vanta

Medtronic announces FDA approval of recharge-free Vanta spinal cord stimulation implant

Medtronic has received US Food and Drug Administration (FDA) approval for Vanta—a high-performance, recharge-free implantable neurostimulator (INS) with a device life that can be...
DTM SCS Medtronic

DTM spinal cord stimulation using Medtronic’s Intellis platform shows superior back...

Three-month results from a large, multicentre randomised controlled trial (RCT) has demonstrated statistically significant (p=0.0009) and superior back pain relief with differential target multiplexed...